-
公开(公告)号：US20150266895A1
公开(公告)日：2015-09-24
申请号：US14431462
申请日：2013-09-26
Applicant: Kevin J. WILSON , David J. WITTER , Phieng SILIPHAIVANH , Kathryn KIPFORD , David SLOMAN , Danielle FALCONE , Brendan O'BOYLE , Umar Faruk MANSOOR , Jongwon LIM , Joey L. METHOT , Christopher BOYCE , Lei CHEN , Matthew H. DANIELS , Salem FEVRIER , Xianhai HUANG , Ravi KURUKULASURIYA , Ling TONG , Wei ZHOU , Joseph KOZLOWSKI , Milana M. MALETIC , Bidhan A. SHINKRE , Jayanth Thiruvellore THATAI , Raman Kumar BAKSHI , Ganesh Babu KARUNAKARAN , MERCK SHARP & DOHME CORP.
Inventor： Kevin J. Wilson , David J. Witter , Phieng Siliphaivanh , Kathryn Lipford , David Sloman , Danielle Falcone , Brendan O'Boyle , Umar Faruk Mansoor , Jongwon Lim , Joey L. Methot , Christopher Boyce , Lei Chen , Matthew H. Daniels , Salem Fevrier , Xianhai Huang , Ravi Kurukulasuriya , Ling Tong , Wei Zhou , Joseph Kozlowski , Milana M. Maletic , Bidhan A. Shinkre , Jayanth Thiruvellore Thatai , Raman Kumar Bakshi , Ganesh Babu Karunakaran
IPC: C07D498/18 , A61K31/437 , A61K31/5377 , A61K31/496 , A61K45/06 , A61K31/4375 , C07D498/14 , A61K31/553 , C07D519/00 , C07D471/04 , C07D471/14
CPC classification number: C07D498/18 , A61K31/437 , A61K31/4375 , A61K31/496 , A61K31/5377 , A61K31/553 , A61K45/06 , C07D471/04 , C07D471/14 , C07D471/16 , C07D498/14 , C07D498/16 , C07D519/00 , A61K2300/00
Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).
Abstract translation: 公开了式（1）的ERK抑制剂及其药学上可接受的盐。 还公开了使用式（1）的化合物治疗癌症的方法。
-
公开(公告)号：US09226922B2
公开(公告)日：2016-01-05
申请号：US14431485
申请日：2013-09-26
Applicant: Merck Sharp & Dohme Corp.
Inventor： Kevin J. Wilson , David J. Witter , Matthew H. Daniels , Angie R. Angeles , Phieng Siliphaivanh , David Sloman , Brendan O'Boyle , Danielle Falcone , Catherine White , Ron Ferguson , Wei Zhou , Kathryn Lipford , Umar Faruk Mansoor , Salem Fevrier , Xianhai Huang , Ravi Kurukulasuriya , Judson E. Richard , Shuyi Tang , Christopher Boyce , Joseph Kozlowski , Raman Kumar Bakshi , Ganesh Babu Karunakaran
IPC: C07D401/14 , A61K31/437 , C07D471/04 , A61K45/06 , A61K31/4545
CPC classification number: A61K31/437 , A61K31/4545 , A61K45/06 , C07D471/04
Abstract: Disclosed are the ERK inhibitors of formula (1.0), having a pyrazolopyridine base structure, and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1.0).
Abstract translation: 公开了具有吡唑并吡啶基结构的式（1.0）的ERK抑制剂及其药学上可接受的盐。 还公开了使用式（1.0）化合物治疗癌症的方法。
-
公开(公告)号：US20210395240A1
公开(公告)日：2021-12-23
申请号：US17287256
申请日：2019-10-28
Applicant: Dane CLAUSEN , Merck Sharp & Dohme Corp.
Inventor： Dane Clausen , Xavier Fradera , Liangqin Guo , Yongxin Han , Shuwen He , Joseph Kozlowski , Guoqing Li , Theodore A. Martinot , Alexander Pasternak , David Sloman , Li Xiao , Wensheng Yu , Rui Zhang
IPC: C07D413/14 , C07D401/14
Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
-
公开(公告)号：US10995085B2
公开(公告)日：2021-05-04
申请号：US16819325
申请日：2020-03-16
Applicant: Merck Sharp & Dohme Corp.
Inventor： Yongxin Han , Abdelghani Achab , Yongqi Deng , Xavier Fradera , Craig Gibeau , Brett A. Hopkins , Derun Li , Kun Liu , Meredeth A. McGowan , Nunzio Sciammetta , David Sloman , Catherine White , Hongjun Zhang , Hua Zhou
IPC: C07D405/10 , A61K31/4523 , A61K45/06 , C07D471/04 , A61K31/437 , A61K31/506 , A61K31/4155 , C07D305/08 , A61K31/337 , C07D417/10 , A61K31/427 , A61K31/41 , A61K31/4245 , A61K31/4184 , C07D405/14 , A61K31/444 , A61K31/513 , C07D413/04 , C07D401/04 , C07D213/56 , A61K31/4418 , C07D417/14 , A61K31/501 , C07D241/12 , A61K31/4965 , A61K31/4427 , C07D263/32 , A61P37/00 , C07D231/12 , A61P35/00 , C07D413/10 , C07D401/12 , C07D405/04 , A61P31/00 , C07D209/46 , C07D413/14
Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.
-
公开(公告)号：US10647705B2
公开(公告)日：2020-05-12
申请号：US16186769
申请日：2018-11-12
Applicant: Merck Sharp & Dohme Corp.
Inventor： Yongxin Han , Abdelghani Achab , Yongqi Deng , Xavier Fradera , Craig Gibeau , Brett A. Hopkins , Derun Li , Kun Liu , Meredeth A. McGowan , Nunzio Sciammetta , David Sloman , Catherine White , Hongjun Zhang , Hua Zhou
IPC: C07D405/10 , A61K31/4523 , A61K45/06 , C07D471/04 , A61K31/437 , A61K31/506 , A61K31/4155 , C07D305/08 , A61K31/337 , C07D417/10 , A61K31/427 , A61K31/41 , A61K31/4245 , A61K31/4184 , C07D405/14 , A61K31/444 , A61K31/513 , C07D413/04 , C07D401/04 , C07D213/56 , A61K31/4418 , C07D417/14 , A61K31/501 , C07D241/12 , A61K31/4965 , A61K31/4427 , C07D263/32 , A61P37/00 , C07D231/12 , A61P35/00 , C07D413/10 , C07D401/12 , C07D405/04 , A61P31/00 , C07D209/46 , C07D413/14
Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.
-
Patent Agency Ranking
6.发明申请公开(公告)号：US20210179607A1
公开(公告)日：2021-06-17
申请号：US16758717
申请日：2018-10-29
Applicant: Merck Sharp & Dohme Corp.
Inventor： Yongqi Deng , Abdelghani Achab , Bridget A. Becker , David Jonathan Bennett , Indu Bharathan , Xavier Fradera , Craig Gibeau , Yongxin Han , Derun Li , Kun Liu , Qinglin Pu , Sulagna Sanyal , David Sloman , Wensheng Yu , Hongjun Zhang
IPC: C07D471/04 , C07D215/14 , A61K45/06
Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
-
公开(公告)号：US09233979B2
公开(公告)日：2016-01-12
申请号：US14431462
申请日：2013-09-26
Applicant: Merck Sharp & Dohme Corp.
Inventor： Kevin J. Wilson , David J. Witter , Phieng Siliphaivanh , Kathryn Lipford , David Sloman , Danielle Falcone , Brendan O'Boyle , Umar Faruk Mansoor , Jongwon Lim , Joey L. Methot , Christopher Boyce , Lei Chen , Matthew H. Daniels , Salem Fevrier , Xianhai Huang , Ravi Kurukulasuriya , Ling Tong , Wei Zhou , Joseph Kozlowski , Milana M. Maletic , Bidhan A. Shinkre , Jayanth Thiruvellore Thatai , Raman Kumar Bakshi , Ganesh Babu Karunakaran
IPC: C07D401/14 , A61K31/437 , C07D498/18 , C07D471/04 , A61K31/5377 , A61K31/496 , C07D471/14 , A61K31/4375 , C07D498/14 , A61K31/553 , C07D519/00 , A61K45/06
CPC classification number: C07D498/18 , A61K31/437 , A61K31/4375 , A61K31/496 , A61K31/5377 , A61K31/553 , A61K45/06 , C07D471/04 , C07D471/14 , C07D471/16 , C07D498/14 , C07D498/16 , C07D519/00 , A61K2300/00
Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).
-
公开(公告)号：US20150258074A1
公开(公告)日：2015-09-17
申请号：US14431485
申请日：2013-09-26
Applicant: Kevin J. WILSON , David J. WITTER , Matthew H. DANIELS , Angie R. ANGELES , Phieng SILIPHAIVANH , David L. SLOMAN , Brendan O'BOYLE , Danielle FALCONE , Catherine WHITE , Ron FERGUSON , Wei ZHOU , Kathryn LIPFORD , Umar Faruk MANSOOR , Salem FEVRIRE , Xianhai HUANG , Ravi KURUKULASURIYA , Judson E. RICHARD , Shuyi TANG , Christopher BOYCE , Joseph KOZLOWSKI , Raman Kumar BAKSHI , Ganesh Babu UNAKARAN , Merck Sharp & Dohme Corp.
Inventor： Kevin J. Wilson , David J. Witter , Matthew H. Daniels , Angie R. Angeles , Phieng Siliphaivanh , David Sloman , Brendan O'Boyle , Danielle Falcone , Catherine White , Ron Ferguson , Wei Zhou , Kathryn Lipford , Umar Faruk Mansoor , Salem Fevrier , Xianhai Huang , Ravi Kurukulasuriya , Judson E. Richard , Shuyi Tang , Christopher Boyce , Joseph Kozlowski , Raman Kumar Bakshi , Ganesh Babu Karunakaran
IPC: A61K31/437 , A61K45/06 , A61K31/4545 , C07D471/04
CPC classification number: A61K31/437 , A61K31/4545 , A61K45/06 , C07D471/04
Abstract: Disclosed are the ERK inhibitors of formula (1.0), having a pyrazolopyridine base structure, and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1.0).
Abstract translation: 公开了具有吡唑并吡啶基结构的式（1.0）的ERK抑制剂及其药学上可接受的盐。 还公开了使用式（1.0）化合物治疗癌症的方法。
-
公开(公告)号：US20200216425A1
公开(公告)日：2020-07-09
申请号：US16819325
申请日：2020-03-16
Applicant: Merck Sharp & Dohme Corp.
Inventor： Yongxin Han , Abdelghani Achab , Yongqi Deng , Xavier Fradera , Craig Gibeau , Brett A. Hopkins , Derun Li , Kun Liu , Meredeth A. McGowan , Nunzio Sciammetta , David Sloman , Catherine White , Hongjun Zhang , Hua Zhou
IPC: C07D405/10 , A61K31/4427 , A61K31/4965 , C07D241/12 , A61K31/501 , C07D417/14 , A61K31/4418 , C07D213/56 , C07D401/04 , C07D413/04 , A61K31/513 , A61K31/444 , C07D405/14 , A61K31/4184 , A61K31/4245 , A61K31/41 , A61K31/427 , C07D417/10 , A61K31/337 , C07D305/08 , A61K31/4155 , A61K31/506 , A61K31/437 , C07D471/04 , A61K45/06 , A61K31/4523 , C07D413/14 , C07D209/46 , A61P31/00 , C07D405/04 , C07D401/12 , C07D413/10 , A61P35/00 , C07D231/12 , A61P37/00 , C07D263/32
Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.
-
公开(公告)号：US20190144433A1
公开(公告)日：2019-05-16
申请号：US16186769
申请日：2018-11-12
Applicant: Merck Sharp & Dohme Corp.
Inventor： Yongxin Han , Abdelghani Achab , Yongqi Deng , Xavier Fradera , Craig Gibeau , Brett A. Hopkins , Derun Li , Kun Liu , Meredeth A. McGowan , Nunzio Sciammetta , David Sloman , Catherine White , Hongjun Zhang , Hua Zhou
IPC: C07D405/10 , A61K31/4427 , A61K45/06 , C07D471/04 , A61K31/437 , A61K31/506 , A61K31/4155 , C07D305/08 , A61K31/337 , C07D417/10 , A61K31/427 , A61K31/41 , A61K31/4245 , A61K31/4184 , C07D405/14 , A61K31/444 , A61K31/513 , C07D413/04 , C07D401/04 , C07D213/56 , A61K31/4418 , C07D417/14 , A61K31/501 , C07D241/12 , A61K31/4965 , A61K31/4523
Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.039 seconds)
